Free Trial

Ascendis Pharma A/S (ASND) Competitors

Ascendis Pharma A/S logo
$179.09 +3.31 (+1.88%)
As of 02:26 PM Eastern

ASND vs. ARGX, ONC, BNTX, TEVA, SMMT, GMAB, ITCI, RDY, VTRS, and QGEN

Should you be buying Ascendis Pharma A/S stock or one of its competitors? The main competitors of Ascendis Pharma A/S include argenx (ARGX), Beigene (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Intra-Cellular Therapies (ITCI), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry.

Ascendis Pharma A/S vs. Its Competitors

Ascendis Pharma A/S (NASDAQ:ASND) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings, risk and community ranking.

Ascendis Pharma A/S has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500. Comparatively, argenex has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500.

argenex has a net margin of 40.20% compared to Ascendis Pharma A/S's net margin of -93.22%. argenex's return on equity of 16.15% beat Ascendis Pharma A/S's return on equity.

Company Net Margins Return on Equity Return on Assets
Ascendis Pharma A/S-93.22% N/A -33.29%
argenex 40.20%16.15%14.33%

argenex received 210 more outperform votes than Ascendis Pharma A/S when rated by MarketBeat users. Likewise, 67.65% of users gave argenex an outperform vote while only 67.30% of users gave Ascendis Pharma A/S an outperform vote.

CompanyUnderperformOutperform
Ascendis Pharma A/SOutperform Votes
457
67.30%
Underperform Votes
222
32.70%
argenexOutperform Votes
667
67.65%
Underperform Votes
319
32.35%

In the previous week, argenex had 15 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 16 mentions for argenex and 1 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.88 beat argenex's score of 0.58 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ascendis Pharma A/S
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
argenex
3 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

argenex has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ascendis Pharma A/S$393.54M27.82-$409.12M-$6.28-28.52
argenex$2.25B15.53$833.04M$16.2135.33

60.3% of argenex shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by insiders. Comparatively, 2.4% of argenex shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Ascendis Pharma A/S currently has a consensus price target of $220.67, indicating a potential upside of 23.22%. argenex has a consensus price target of $729.93, indicating a potential upside of 27.45%. Given argenex's stronger consensus rating and higher possible upside, analysts clearly believe argenex is more favorable than Ascendis Pharma A/S.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ascendis Pharma A/S
0 Sell rating(s)
0 Hold rating(s)
15 Buy rating(s)
0 Strong Buy rating(s)
3.00
argenex
0 Sell rating(s)
1 Hold rating(s)
17 Buy rating(s)
2 Strong Buy rating(s)
3.05

Summary

argenex beats Ascendis Pharma A/S on 16 of the 19 factors compared between the two stocks.

Get Ascendis Pharma A/S News Delivered to You Automatically

Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ASND vs. The Competition

MetricAscendis Pharma A/SMED IndustryMedical SectorNASDAQ Exchange
Market Cap$10.95B$2.83B$5.40B$8.72B
Dividend YieldN/A2.69%5.38%4.23%
P/E Ratio-28.5221.4425.7719.48
Price / Sales27.82284.23399.87109.45
Price / CashN/A40.9225.4426.73
Price / Book-95.267.397.985.75
Net Income-$409.12M-$55.10M$3.15B$248.52M
7 Day Performance3.58%1.04%2.12%2.09%
1 Month Performance10.55%8.10%6.92%5.54%
1 Year Performance38.41%-1.48%38.60%16.58%

Ascendis Pharma A/S Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ASND
Ascendis Pharma A/S
2.6433 of 5 stars
$179.09
+1.9%
$220.67
+23.2%
+37.5%$10.95B$393.54M-28.521,017
ARGX
argenx
4.4005 of 5 stars
$551.22
-4.6%
$709.18
+28.7%
+37.1%$33.66B$2.58B-626.39650Analyst Forecast
ONC
Beigene
1.3559 of 5 stars
$264.42
-1.9%
$319.00
+20.6%
N/A$28.95B$4.18B-32.099,000Gap Down
BNTX
BioNTech
2.5107 of 5 stars
$106.33
-0.2%
$137.86
+29.7%
+21.7%$25.56B$2.75B-50.633,080
TEVA
Teva Pharmaceutical Industries
4.4216 of 5 stars
$17.50
+3.0%
$24.44
+39.7%
+0.0%$20.07B$16.62B-12.0736,800
SMMT
Summit Therapeutics
3.2924 of 5 stars
$19.95
+0.9%
$35.09
+75.9%
+157.1%$14.82B$700K-71.25110Analyst Downgrade
GMAB
Genmab A/S
3.9202 of 5 stars
$22.86
+0.2%
$39.17
+71.3%
-20.6%$14.66B$3.12B13.141,660
ITCI
Intra-Cellular Therapies
0.9293 of 5 stars
$131.87
flat
$109.70
-16.8%
N/A$14.05B$680.50M-151.57560
RDY
Dr. Reddy's Laboratories
1.7908 of 5 stars
$15.69
-0.7%
$16.95
+8.0%
+7.0%$13.10B$325.54B24.9924,800Positive News
VTRS
Viatris
2.6736 of 5 stars
$8.99
+0.8%
$10.40
+15.7%
-15.5%$10.55B$14.33B-12.1537,000
QGEN
Qiagen
3.0292 of 5 stars
$47.46
+0.7%
$48.42
+2.0%
+14.8%$10.55B$2.00B132.166,030Analyst Forecast

Related Companies and Tools


This page (NASDAQ:ASND) was last updated on 6/24/2025 by MarketBeat.com Staff
From Our Partners